|
Time point
|
Dx
|
Last measurement prior to start of IV iloprost
|
|---|
|
Subjects (n)
|
50
|
50
|
|
Age (years)
|
42 (29-58)
|
44 (31-63)
|
|
Interval diagnosis and initiation of iloprost (month)
| |
34 (20-47)
|
|
Female/male
|
34/16
|
34/16
|
|
NYHA class II/III/IV
|
7/30/13
|
1/24/24
|
|
6MWD (m)
|
332 (229-434)
|
289 (132-370) #
|
|
PAH-specific therapy
|
Initial therapy
| |
|
Sildenafil alone
|
11 (22%)
|
0 (0%)
|
|
ERA alone
|
22 (44%)
|
2 (4%)
|
|
Inhaled Iloprost alone
|
8 (16%)
|
0 (0%)
|
|
Sildenafil + ERA
|
6 (12%)
|
14 (28%)
|
|
Sildenafil + inhaled Iloprost
|
3 (6%)
|
3 (6%)
|
|
ERA + inhaled Iloprost
|
0 (0%)
|
5 (10%)
|
|
Triple therapy
|
0 (0%)
|
26 (52%)
|
|
Hemodynamics
|
n = 50
|
n = 26
|
|
PRA (mmHg)
|
7 (3-13)
|
12 (7-16) #
|
|
Ppa (mmHg)
|
59 (48-68)
|
56 (49-65)
|
|
Ppcw (mmHg)
|
7 (5-9)
|
9 (7-11)
|
|
CI (L/min/m2)
|
2.0 (1.5-2.3)
|
1.7 (1.4-1.9)
|
|
PVR (dyn*s*cm-5)
|
1, 251 (852-1, 705)
|
1, 205 (954-1, 499)
|
|
SVO2 (%)
|
58 (54-66)
|
58 (54-69)
|
- Characteristics at diagnosis (Dx) and start of intravenous iloprost. Absolute values are given regarding PAH-specific therapy, functional class and gender. Age, interval from Dx to BL-ilo, 6MWT and hemodynamic parameters are given as median (interquartile range; IQR). #: p < 0.05 vs Dx.
